Company ProfilePremium

BIFIDO Co., Ltd

Company Profile Analysis

Ticker: 238200.KQ주식회사 비피도

ESOMAR 23 Corporate BadgeISO Certifications Badge
BIFIDO Co., Ltd - Company showcase

Year Founded & Workforce

1999

83 Employees

BIFIDO Co., Ltd logo

BIFIDO Co., Ltd Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

BIFIDO Co., Ltd Overview

BIFIDO is a small-cap Korean microbiome company built on human-derived Bifidobacterium strains. The core strains, B. bifidum BGN4 and B. longum BORI, were isolated in 1994 from the guts of Korean infants by founder Professor Ji Geun-eog's research team. Commercially, BIFIDO is mainly a contract (ODM) manufacturer of probiotic health-functional foods: ODM made up 74.6% of FY2025 standalone sales. It also sells branded finished goods (BIFIDOLAB, Zigunuk), almost entirely outside Korea, and bulk strain powders. Its main technical differentiator is regulatory credentialing. BIFIDO describes itself as the first Korean company, and the sixth globally, to hold both US FDA NDI and GRAS status for proprietary strains (BGN4, BORI, AD011). BGN4 is also listed in the US Pharmacopeia. After the 2024 embezzlement crisis, Whan In Pharmaceutical took control. BIFIDO has since retreated from clinical-stage live biotherapeutics, sold its Seoul Microbiome Center for KRW 25.4bn, and refocused on individually-recognised functional ingredients and an early-stage engineered-bifidobacteria (BiGeX/eLBP) platform.


Company's own description (FY2025 business report, paraphrased)

BIFIDO launched its first probiotic finished product in 2001. After Korea's Health Functional Food Act took effect in 2002, it began manufacturing and selling probiotic strain powders ("raw powder", 원말) and health functional foods containing them; the H1 2026 report dates this to March 2004. It runs its own brand BIFIDOLAB, among others, and provides ODM services to domestic and overseas brand owners from a GMP-certified facility. Its proprietary Microbiome Accelerating Platform (MAP) consolidates more than 30 years of gut-microbe isolation, culture and industrialisation know-how. MAP supports functional-probiotic and microbiome-therapeutic development. The company states that its rheumatoid arthritis live-biotherapeutic candidate reached a domestic Phase 1 IND application, but that the application was voluntarily withdrawn in H2 2025 because of legal barriers and insufficient commercial viability. The next-generation programme is BiGeX (Bifidobacterium Gene Expression & Delivery Platform), which aims to create engineered live biotherapeutic products (eLBPs) in which recombinant Bifidobacterium expresses and delivers therapeutic proteins in vivo.

Business model and revenue model

Revenue streamModelFY2025 share of standalone sales (%)Notes
ODM finished productsProduct sales to brand owners (B2B); made-to-specification, high-mix/low-volume74.6Domestic ODM KRW 12,624m; overseas ODM KRW 1,376m
Own-brand finished productsProduct sales via overseas local distributors (B2B2C)13.1Own-brand domestic sales were zero in FY2025 and H1 2026
Raw powder (strain powders)Ingredient sales to manufacturers (B2B)12.3Export via local distributors to local manufacturers; domestic direct to manufacturers
Merchandise (상품)Resale of purchased goods (toothpaste, cosmetics, others)About 4.9 of consolidated revenue (KRW 961m of 19,679m)Consolidated note 4
Licensing / royaltiesNot a reported revenue line0Pipeline out-licensing is an aspiration (BiGeX), not a current revenue source
Subscription / services—0—

All revenue is recognised at a point in time (K-IFRS 1115 note). BIFIDO reports a single operating segment.

Value-chain position

BIFIDO is vertically integrated across strain discovery and isolation, culture and fermentation (35,000-litre fermenter capacity at Hongcheon, per 2018 IPO coverage), freeze-drying, coating and stabilisation (it holds a patented vitamin A/C/E antioxidant coating method, granted Jun 2025), finished-dose manufacturing (stick-pack powders and capsules), and regulatory dossier preparation (GRAS, NDI, Halal, Kosher, China FSMP factory certification). It does not run large-scale domestic B2C retail; brand marketing to Korean consumers is done by its ODM customers. Raw materials are mainly oligosaccharide preparations, sugar preparations, corn starch and packaging film, bought in what the company calls a fully competitive supplier market.

Customer types and end-markets

Customer typeEnd-marketEvidence
Korean health-functional-food brand ownersDomestic probiotic supplementsDomestic ODM KRW 12,624m in FY2025 (67.3% of standalone sales)
Overseas distributors (mainly China)Chinese consumer probiotics via direct-selling / distributor channelsOwn-brand exports KRW 2,454m in FY2025; 2024 Chinese direct-selling licence policy change hurt sales
Overseas brand ownersOverseas ODMKRW 1,376m in FY2025
Domestic and overseas food/supplement manufacturersIngredient (raw-powder) market, including infant formula use cases supported by GRAS noticesRaw powder KRW 2,304m in FY2025
Pet-food / pet-supplement channelCompanion-animal probiotics (about 33 products launched)FY2025 report, business objective added 2021

Customer concentration. Customer "A" accounted for KRW 5,990m, or 31.93% of FY2025 standalone revenue (KRW 2,160m in FY2024). The three largest finished-product customers (A, B, C) together accounted for 49.3% of FY2025 standalone revenue. In H1 2026, customer A's sales fell to KRW 762m (12.5%) from KRW 3,078m in H1 2025.

Independent characterisation

BIFIDO is economically a sub-scale probiotic ODM and ingredient house: FY2025 consolidated revenue was KRW 19.7bn. It carries a disproportionately large intangible base (strain IP, US regulatory status) and has a history of ambitious but unfunded biotech optionality. Revenue swings with a few ODM customers and with Chinese channel regulation. Despite the "microbiome therapeutics" listing narrative, more than 95% of revenue comes from commodity-like probiotic manufacturing. The 2026 sale of the Gangnam Microbiome Center turned an illiquid real-estate commitment into cash, materially changing the balance-sheet profile against a market capitalisation of about KRW 22bn.

Strategy

Stated strategy (themes paraphrased from the FY2025 business report and H1 2026 report)

  1. Strengthen fundamentals first. After withdrawing the RA IND, management says it will prioritise "inner strength", consolidate the competitiveness of the core probiotic business, and pursue innovative therapeutics only over the medium to long term.

  2. Move up the value chain in ingredients. Shift from commodity "notified" probiotics, which any manufacturer can produce, to individually-recognised ingredients with an exclusivity period. The company cites a Korean individually-recognised HFF market of about KRW 740.9bn in 2023.

  3. Monetise exclusive ingredients through B2B, then B2C. Use existing OEM/ODM channels first; extend to own-brand online B2C after approvals.

  4. Premium niches: pet food and supplements, and global infant formula (China infant-strain list registration).

  5. China channel diversification: CBEC, multiple distribution partners with evaluation systems, and balanced direct-selling and ODM models.

  6. Platform R&D: BiGeX eLBP platform for solid tumours and infections, developed with a government-funded research institute and positioned for co-development and licensing.

Initiatives in the last 24 months

InitiativeDateDescriptionStatus
Governance overhaulOct 2024 → Mar 2026Audit committee, independent directors, 3% ruleImplemented
RA programme exitH2 2025Phase 1 IND voluntarily withdrawn; BFD1R01/BFD1R02 suspendedCompleted
Microbiome Center monetisationSep 2025 – Aug 2026Held-for-sale classification; KRW 25.4bn sale to Kim YJ Co., Ltd.; stated uses are debt repayment, liquidity, new factory and capacityClosed 14 Aug 2026
Individually-recognised ingredients2025–2027Hypersensitive skin (in MFDS review); body fat (filing targeted Aug 2026)In progress
China infant-strain registration2026–2029Clinical preparationEarly stage
BiGeX eLBP platformOngoingBFDe001 (solid tumour), BFDe002 (rCDI)Discovery / in vitro
Strategic financial investmentAug 2025KRW 7.0bn equity-linked bond (FVTPL; fair value KRW 6.4bn at Jun 2026)Held
Parent synergiesFrom Sep 2024Whan In plans links with its health-food distribution subsidiary AsU (애즈유). In 2025 Whan In partly disposed of treasury shares, citing funding for health-functional-food (BIFIDO) and animal-health upgradesOngoing; no quantified synergy disclosed
Pet probiotics and diagnosticsOngoingAbout 33 pet products; saliva-based diagnostic kit in developmentOngoing

ESG and sustainability commitments

None disclosed: no emissions targets, sustainability report or ESG policy were identified.

Medium-term financial targets / guidance

Not publicly disclosed. BIFIDO does not publish revenue or margin guidance.

Products & Services

Proprietary probiotic strains (raw-material platform)

StrainOrigin / depositRegulatory statusClaimed / studied functionsTarget customer
Bifidobacterium bifidum BGN4Breast-fed infant faeces; KCCM 80046US FDA GRAS GRN 814 (2019); NDI 1079 (2018); USP listing; Halal; KosherImmune modulation, diarrhoea, ulcerative colitis, IBS, cognition, mood, acute kidney injury, eczema. Patents cover renal failure, COVID-19, osteoarthritis, anti-rotavirus (with BORI), livestock disease, recombinant anti-inflammatory and anti-cancer (scFv) usesSupplement and food manufacturers; infant formula
Bifidobacterium longum BORIBreast-fed infant faeces; KCCM 10492GRAS GRN 813 (2019); NDI 1082 (2018); Halal; KosherAnti-rotavirus (Severance Hospital study), cognition, mood, AKI; COVID-19, osteoarthritis and livestock patents (2025–26)Same as above
Bifidobacterium animalis ssp. lactis AD011Breast-fed infant faeces; KCCM 11209GRAS GRN 952 (2021, after GRN 875 withdrawal in 2019); NDI 1118 (2019); Halal; KosherIBS, eczema; livestock-disease patent (2025)Same as above
B. longum RAPOKCTC13773BPKosherRA (KR, US, CN patents), cancer prevention, immune balance (with L. plantarum LRC5264), systemic sclerosis / pulmonary fibrosis (patent May 2026)Former therapeutic candidate; ingredient
B. pseudocatenulatum C-RAPO and B. bifidum ATTKCTC13986BP / KCTC13474BPKosher (ATT)Sjögren's syndrome (KR and two US patents); RAResearch / ingredient
L. gasseri HHuMIN-D and L. fermentum / Lacticaseibacillus paracasei OKHuman oral originKosherHalitosis and dental caries (KR patents 2020, 2024, 2025); halitosis reduction study at Dankook UniversityOral-care ingredient (individually-recognised track halted at human-study stage)
L. salivarius HHuMin-U—KosherUTI, vaginitis/vulvitis (patent Jan 2025), anti-norovirus (patent Mar 2026)Women's health ingredient
L. helveticus GUT10—KosherUTI (patent 2021)Ingredient
L. sakei RH1117; L. gasseri HHuMin-R——RA (patents 2021–22)Research
Weissella confusa VP30—KosherConstipation (EPS-producing; fermented-milk and jelly product commercialised), skin moisturising (cosmetic patent 2023), skin-barrier essenceFood and cosmetics
Lactiplantibacillus plantarum ND88—2024 SME-ministry support project for FDA GRAS; dental-caries patent (Mar 2025)Oral healthIngredient (GRAS pursuit; outcome not disclosed)
L. acidophilus AD031; L. casei IBS041—Halal; KosherGeneral probioticIngredient
Other Kosher-listed strainsB. breve BH12, B. infantis BH07, L. bulgaricus BH047, L. helveticus BH14, L. paracasei CH88, L. plantarum BH02, L. reuteri BH11, L. rhamnosus BH09, L. salivarius BH15, Lactococcus lactis BH10Kosher (Orthodox Union)General probiotic libraryIngredient

Launch years and pricing for individual strains are not publicly disclosed. Average realised raw-powder export prices were KRW 363,858/kg (FY2023), KRW 401,252/kg (FY2024), KRW 459,966/kg (FY2025) and KRW 477,656/kg (H1 2026). Domestic raw-powder averages are heavily mix-driven: KRW 211,598/kg (FY2023) versus KRW 11,825/kg (FY2025).

Finished products

LineBrand(s)DescriptionChannelLaunchPricing
Own-brand bifidus supplementsBIFIDOLAB; Zigunuk / 지근억비피더스 (including "Zigunuk Bifidus Premium"; "Family Biome" referenced in 2021 broker coverage)Bifidus-based probiotic powders and capsulesExported via local distributors (mainly China); no domestic own-brand sales in FY2025 or H1 2026Zigunuk Bifidus 2001Average finished-product export price KRW 220.58 per unit (FY2025)
ODM probioticsCustomer brands; company references "Bifigen" (비피젠) and others; "Lacfido" (락피도) cited as an ODM product in 2021 broker coverageMade-to-order probiotic HFFs (stick packs, capsules)Domestic and overseas brand ownersOngoingAverage domestic finished-product price KRW 205.07 per unit (FY2025)
Pet probiotics—About 33 companion-animal probiotic products under the Feed Control Act; saliva-based pathogen diagnostic kit in developmentPet channelBusiness objective added Mar 2021—
Functional foods—Constipation-relief fermented-milk jelly (VP30)—Productised (date not disclosed)—
Cosmetics and personal care—Bifidus-expression and VP30-based cosmetic ingredients (essence, serum; GLP-tested acne and itch claims); merchandise includes toothpaste and cosmeticsB2B / merchandise——

Development portfolio (ingredients)

ProgrammeFunctional claimStatus (H1 2026 report)Target
Hypersensitive-immune skin improvementIndividually-recognised HFF ingredientUnder MFDS reviewApproval H1 2027; commercial launch H2 2027
Body-fat reductionIndividually-recognised HFF ingredient (heat-killed / probiotic)Paper published (by Mar 2026); dossier in final preparationMFDS filing targeted Aug 2026 (submission not yet confirmed publicly)
Halitosis reliefIndividually-recognised ingredientHuman study halted; paper published Jun 2025Discontinued at human-study stage
Cognitive improvementIndividually-recognised ingredientHuman study haltedDiscontinued
China infant-strain food list registrationMarket access for infant products in ChinaPreparing clinical studyRegistration 2028; commercialisation 2029

Therapeutics pipeline

CandidateIndicationModalityStatus
BFD1R01Rheumatoid arthritisNatural live biotherapeuticDevelopment suspended. Investigational product made at a GMP CMO; Phase 1 IND filed then voluntarily withdrawn (H2 2025)
BFD1R02Idiopathic pulmonary fibrosisNatural live biotherapeuticSuspended alongside BFD1R01
BFDe001Solid tumourseLBP (immunotoxin-expressing Bifidobacterium)Expression confirmed; in vitro testing
BFDe002Recurrent C. difficile infectioneLBP (endolysin-expressing)Constructing vector and strain

Financial Narrative

Basis and sources.

  • FY2023–FY2025: DART consolidated statements (FY2025 business report).

  • FY2021–FY2022: S&P Global-normalised data (StockAnalysis), consistent with Butler/Value Line summaries of DART data.

  • Operating income for FY2024 and FY2025 uses DART figures (KRW −4,492m and KRW +1,403m). S&P reports KRW −4,968m and KRW +1,867m because it classifies other operating items differently.

  • FY2025 standalone (parent-only) results were revenue KRW 18,758m, operating income KRW 1,494m and net income KRW +1,158m. Some aggregators quote these instead of consolidated figures (consolidated net income was KRW −193m).

Income statement

Revenue CAGR, FY2021–FY2025: 12.9% a year. The path was highly non-linear: +20%, +28%, −34%, +59%.

Interim update (consolidated, KRW m; H1 2026 semi-annual report):

The H1 2026 net profit is non-operating. It reflects a KRW 3,032m equity-method gain as Ropi Bio's third-party placements lifted its net assets (from KRW −4.2bn to KRW +53.9bn), plus a KRW 688m fair-value gain on the FVTPL bond. Q2 2026 on its own: revenue KRW 3,602m (versus KRW 6,197m), operating loss KRW −410m (versus a profit of KRW +1,339m).

Trend commentary.

  1. Revenue. FY2022–FY2023 growth was export-led: FY2023 standalone exports were KRW 9,085m, 53% of sales. The 2024 collapse came from China (exports −56%), compounded by the embezzlement-related trading halt and management distraction. FY2025 recovered on domestic ODM (+67%), concentrated in one customer. H1 2026 reverses most of that gain.

  2. Gross margin stays in a 34–40% band when utilisation is normal. It fell to 26.6% in FY2024 on under-absorption, which the CEO's May 2024 letter attributed to lower utilisation as China sales fell.

  3. Operating leverage is severe. SG&A including R&D is semi-fixed at about KRW 6–8bn, so a ±KRW 6bn revenue swing moves operating income by about KRW 4–6bn.

  4. Below the line, results were repeatedly hit by associate losses (Ropi Bio), CB-related charges in 2023–24 and fair-value moves. FY2021 net income of KRW 4.5bn included a KRW 7.2bn asset-disposal gain (S&P-normalised data; the asset was not identified in the filings reviewed). Reported net income therefore says little about core earnings power.

Balance sheet

Notes:

  • FY2025 working capital includes the KRW 24,844m of held-for-sale real estate. Excluding it, working capital was KRW −1,784m.

  • FY2023 also carried derivative liabilities of KRW 5,376m linked to the CB, which are not included in debt above.

  • At 30 Jun 2026: total assets KRW 64,212m; cash KRW 7,610m; bank debt KRW 10,000m (Woori Bank, 3.94%, maturing 10 Aug 2026, secured on the Daechi-dong property); equity KRW 48,936m; FVTPL bond KRW 6,415m; Ropi Bio KRW 6,268m.

Cash flow

Capex history is dominated by the Gangnam Microbiome Center: land bought April 2021, construction May 2023 to July 2025. FY2021–FY2025 capex totalled KRW 32.3bn. The KRW 25.4bn sale in 2026 recovers most of it in cash. Investing flows in 2023–2025 also included large short-term loans to third parties: KRW 13.0bn in 2023 and KRW 22.35bn in 2024, with KRW 15.0bn collected in 2025. The borrowers were not identified in the sources reviewed.

Ratios

Methodology:

  • ROIC = operating income × (1 − 22% notional tax) ÷ (year-end equity + total debt).

  • FY2025 current ratio is 0.88x excluding held-for-sale assets.

  • Net debt/EBITDA is shown only for net-debt years with positive EBITDA.

  • Working-capital days use year-end balances.

  • S&P TTM metrics (Aug 2026): ROE 4.79%, ROIC 1.86%, Altman Z-score 2.15, Piotroski F-score 6.

Inflections and drivers. Return metrics have never sustainably cleared the cost of capital (S&P estimates WACC at 7.29%). The balance sheet swung from a KRW 21bn net-cash position (FY2021) to net debt (FY2024–FY2025). The causes were real-estate capex, CB redemption, third-party loans and the embezzlement. The August 2026 property sale should restore a net-cash position, subject to confirmation of the Woori Bank loan repayment. The FY2025 cash conversion cycle (96 days) is the best in five years because inventory fell from KRW 2,940m to KRW 1,921m.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Revenue by Segment and Revenue by Segment (%)

MetricFY2023FY2024FY2025

Own-brand finished products revenue (KRW Mn)

4,8821,8592,454

ODM finished products revenue (KRW Mn)

10,9978,60314,000

Raw powder revenue (KRW Mn)

1,2671,6182,304

Total standalone revenue (KRW Mn)

17,14612,08018,758

Own-brand share of total (%)

28.515.413.1

ODM share of total (%)

64.171.274.6

Raw powder share of total (%)

7.413.412.3

Own-brand YoY growth (%)

—-61.932.0

ODM YoY growth (%)

—-21.862.7

Raw powder YoY growth (%)

—27.742.4

Total standalone YoY growth (%)

—-29.555.3

Revenue by Segment

MetricFY2024FY2025

Products revenue (KRW Mn)

11,53818,718

Merchandise revenue (KRW Mn)

812961

Total consolidated revenue (KRW Mn)

12,35019,679

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Segment Revenue

CategoryH1 2026 revenueShare (%)

Own-brand finished (BIFIDOLAB and others)

2634.3

ODM finished ("Bifigen" and others)

4,55874.9

Raw powder (BGN4 and others)

1,26520.8

Total

6,086100.0

Income Statement and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (KRW Mn)

12,11714,57918,63412,35019,679

Revenue growth YoY (%)

-2.120.327.8-33.759.3

Cost of sales (KRW Mn)

7,9828,71711,2119,06512,189

Gross profit (KRW Mn)

4,1355,8627,4233,2857,490

SG&A incl. R&D (KRW Mn)

5,1524,5997,7677,7766,087

Operating income (KRW Mn)

-1,0171,263-344-4,4921,403

Depreciation & amortisation (KRW Mn)

1,7461,7291,8731,9311,955

EBITDA = operating income + D&A (KRW Mn)

7292,9921,529-2,5613,358

Share of associate loss (KRW Mn)

——-1,555-1,764-1,239

Pre-tax income (KRW Mn)

6,5411,808139-6,819-484

Income tax expense (benefit) (KRW Mn)

2,048263-943-1,424-291

Net income (KRW Mn)

4,4931,5461,082-5,395-193

EPS basic (KRW)

551189132-660-24

EPS diluted (KRW)

551189132-660-24

Dividends per share (KRW)

00000

Gross margin (%)

34.140.239.826.638.1

Operating margin (%)

-8.48.7-1.8-36.47.1

EBITDA margin (%)

6.020.58.2-20.717.1

Net margin (%)

37.110.65.8-43.7-1.0

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Margin Analysis (%)

MetricH1 2025H1 2026Change (%)

Revenue

11,1456,097-45.3

Gross profit

4,6531,749-62.4

Operating income

1,418-1,007

n/m

Share of associate result (Ropi Bio)

-6993,032

n/m

Pre-tax income

1,1102,973167.9

Net income

9442,986216.2

Domestic revenue

6,7014,396-34.4

Overseas (China etc.) revenue

4,4441,702-61.7

Balance Sheet

MetricFY2021FY2022FY2023FY2024FY2025

Total assets (KRW Mn)

54,64854,93771,73761,21261,302

Cash and cash equivalents (KRW Mn)

4,5278495,8061,7587,664

Short-term financial instruments (KRW Mn)

16,48918,46421,50200

Short-term loans receivable, net (KRW Mn)

———14,882350

Assets held for sale (KRW Mn)

000024,844

Property, plant and equipment (KRW Mn)

25,58225,28226,88331,59112,113

Goodwill and intangibles (KRW Mn)

1731501136570

Investments in associates (KRW Mn)

——6,2054,4773,238

Short-term bank borrowings (KRW Mn)

00010,70012,000

Convertible bonds (KRW Mn)

0011,37600

Lease liabilities (KRW Mn)

215404240265253

Total debt (KRW Mn)

21540411,61610,96512,253

Short-term portion of debt (KRW Mn)

11419811,51810,85012,135

Long-term portion of debt (KRW Mn)

10120698115119

Net cash (+) / net debt (−) (KRW Mn)

20,80118,90915,692-9,207-4,589

Total equity (KRW Mn)

50,64252,48951,70246,68645,930

Working capital (KRW Mn)

21,63121,96017,7628,46823,060

Cash Flow

MetricFY2021FY2022FY2023FY2024FY2025

Operating cash flow (KRW Mn)

2,0361,8762,849-7163,950

Capital expenditure, PP&E (KRW Mn)

-14,633-1,049-3,292-6,108-7,194

Free cash flow (KRW Mn)

-12,597827-443-6,824-3,244

Dividends paid (KRW Mn)

00000

Share buybacks (KRW Mn)

00000

Interest paid (KRW Mn)

101826178389

Net debt issued / (repaid) (KRW Mn)

-119-13516,808-6,5001,143

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2021FY2022FY2023FY2024FY2025

Return on equity (%)

8.93.02.1-11.0-0.4

Return on assets (%)

8.22.81.7-8.1-0.3

ROIC (%)

-1.61.9-0.4-6.11.9

Current ratio (x)

6.9812.621.901.602.55

Debt to equity (x)

0.000.010.220.230.27

Net debt to EBITDA (x)

————1.37

Interest coverage, operating income ÷ interest expense (x)

-106.669.2-1.3-6.23.6

Asset turnover (x)

0.220.270.290.190.32

Days sales outstanding (days)

39.147.557.750.148.4

Days inventory outstanding (days)

112.884.087.4118.457.5

Days payables outstanding (days)

16.36.120.618.99.9

Cash conversion cycle (days)

135.6125.4124.5149.696.0

Revenue by Region and Revenue by Region (%)

MetricFY2023FY2024FY2025

Domestic (Korea) revenue (KRW Mn)

8,0618,11913,583

Overseas (China etc.) revenue (KRW Mn)

10,5734,2316,096

Total consolidated revenue (KRW Mn)

18,63412,35019,679

Domestic share (%)

43.365.769.0

Overseas share (%)

56.734.331.0

Domestic growth YoY (%)

—0.767.3

Overseas growth YoY (%)

—-60.044.1

Revenue by Region and Revenue by Region (%) — Finished products export

MetricFY2023FY2024FY2025

Finished products export (KRW Mn)

8,0282,9513,830

Finished products domestic (KRW Mn)

7,8517,51112,624

Raw powder export (KRW Mn)

1,0571,0101,345

Raw powder domestic (KRW Mn)

211609959

Total export (KRW Mn)

9,0853,9615,175

Total domestic (KRW Mn)

8,0618,11913,583

Export share of standalone revenue (%)

53.032.827.6

Export growth YoY (%)

—-56.430.7

Share Price History

DatePriceContextSource

26 Dec 2018

18000 (9000 split-adjusted)

IPO offer price; opened at 36,000

Biospectator

18 Jun 2021

12,300

Intraday after US prebiotic patent; market cap about KRW 100.2bn

Aju News

Sep 2021

16,829

Reference price at Amicogen acquisition (deal implied about 24,490/share)

Dealsite

22 Mar 2022

8,850

Option grant-date price

FY2025 notes

23 Mar 2023

8,180

Option grant-date price

FY2025 notes

27 Mar 2024

6,200

Option grant-date price

FY2025 notes

30 Aug 2024

6,112

Whan In control-block price (stock suspended)

Smart Today

16 Jul 2026

2,420—

StockHub

11 Aug 2026

2,580—

Investing.com

28 Aug 2026

2,790—

Value Line Korea

30 Sep 2026

2,670

Latest close retrieved

StockAnalysis

Change by Horizon

HorizonChangeBasis

1-year

−28% to −38%

Aggregator data, Aug–Sep 2026

About 3.5-year

−67%

Versus KRW 8,180 in Mar 2023

About 5-year

−78%

Versus KRW 12,300 in Jun 2021

Since IPO

−70%

Versus split-adjusted KRW 9,000

Valuation Multiples

MultipleBIFIDOBasisCell Biotech (peer)

P/E (x)

11.8

TTM net income KRW 1,849m, inflated by the KRW 3.0bn associate gain

8.52

P/B (x)

0.45

Equity KRW 48,936m

1.05

P/S (x)

1.49

TTM revenue KRW 14,631m

n/v

EV/Sales (x)

1.67

EV KRW 24,449m (Jun-26: market cap + debt KRW 10,218m − cash KRW 7,610m)

n/v

EV/EBITDA (x)

34.2

TTM EBITDA about KRW 714m (DART operating income −1,022 + D&A about 1,736); low-quality denominator

n/v

Pro forma EV after asset sale (KRW Mn, illustrative)

About 1,600

Assumes the KRW 22.86bn balance was received and the KRW 10.0bn Woori loan repaid at maturity; excludes the FVTPL bond (KRW 6.4bn) and Ropi Bio stake (KRW 6.3bn)

—

Share Count (million) and Capital Markets Data

MetricFY2021FY2022FY2023FY2024FY2025

Dividends per share (KRW)

00000

Shares outstanding, year-end (million)

8.188.188.188.188.18

Share buybacks (KRW Mn)

00000

Total debt, year-end (KRW Mn)

21540411,61610,96512,253

Analyst Conclusions

Management guidance and consensus

Guidance: none. Management communicates milestone targets instead of financial guidance: body-fat ingredient filing (Aug 2026 target), hypersensitive-skin approval (H1 2027) with commercial launch (H2 2027), and China infant-strain registration (2028) with commercialisation (2029).

Consensus: no coverage.

Run-rate: on reported trends, FY2026 revenue would be about KRW 12–15bn (H1 2026 KRW 6.1bn; H2 is seasonally stronger per company commentary), with an operating loss unless ODM orders recover. This is an analyst extrapolation, not a forecast.

Bull case

  1. Balance-sheet asymmetry. If the Woori loan was repaid from sale proceeds, pro forma cash is about KRW 20bn and bank debt is zero. Adding the FVTPL bond (KRW 6.4bn) and the Ropi Bio stake (KRW 6.3bn book), non-operating assets exceed the KRW 21.8bn market cap, so the core business trades near zero EV. The stock trades at 0.45x book.

  2. Demonstrated operating leverage. FY2025 produced KRW 1.4bn operating income and KRW 3.4bn EBITDA on KRW 19.7bn revenue, with a 38% gross margin. A return to FY2025-level volumes, possibly helped by Whan In / AsU channels, restores profitability quickly.

  3. Ingredient re-rating optionality. Credentials (GRAS/NDI/USP) plus a near-term individually-recognised approval (H1 2027 target) could move the mix toward exclusive, higher-priced ingredients. Export raw-powder pricing has already risen 31% since FY2023.

Bear case

  1. Core business deteriorating. H1 2026 revenue fell 45% and the operating result swung to a KRW 1.0bn loss as customer A's orders dropped 75% and China fell 62%. ODM concentration means visibility is minimal.

  2. Capital-allocation and governance discount is earned. The record includes an embezzlement, third-party lending, a written-off equity stake, Level-3 bond investments, and a real-estate project built then sold. Sale proceeds may again go to non-core uses, including the stated "new factory" capex while utilisation is falling.

  3. The biotech narrative has collapsed. The RA IND was withdrawn after years of promised clinical entry (targets of 2020, then 2025). The eLBP platform is pre-clinical and faces novel GMO regulation. No sell-side support and a thin, flagged float (May 2026 investment caution) limit any re-rating path.

Catalysts and monitorables (next 12 months)

TimingCatalyst / monitorable
Mid-Nov 2026Q3 2026 report: confirmation of loan repayment, use of KRW 22.86bn proceeds, Q3 revenue trend (customer A, China)
Q4 2026Confirmation of MFDS filing for the body-fat ingredient (Aug 2026 target)
Q4 2026 – Q1 2027Any announcement on the Hongcheon new-factory capex scope and budget
OngoingRopi Bio financing and pipeline (drives equity-method results and impairment risk)
OngoingFVTPL bond conversion, redemption or fair-value changes
Mar 2027FY2026 business report and AGM (dividend or capital-return policy, board changes)
H1 2027MFDS decision on the hypersensitive-skin ingredient
OngoingWhan In actions: stake changes, intra-group distribution deals, possible tender or merger

Analyst verdict

BIFIDO is no longer the "Korean microbiome pioneer" its 2018 IPO advertised. It is now a sub-scale probiotic ODM and ingredient manufacturer, with genuinely valuable regulatory and IP assets attached to a history of poor capital stewardship.

The investment debate has narrowed to two questions. Will the controlling shareholder deploy the newly freed cash productively? And can the ingredient strategy reduce dependence on a few ODM customers and on Chinese channel policy?

On the first question, the August 2026 property sale is the most important event since the Whan In takeover. If, as appears likely though unconfirmed, the KRW 10bn secured loan was retired, BIFIDO holds net cash of about KRW 20bn plus about KRW 12.7bn of book-value financial and associate assets. Together these exceed its market capitalisation, and the stock trades at under half of book value. That provides a meaningful valuation floor, though not a catalyst, because minority shareholders cannot compel distributions and the company has never paid a dividend.

On the second question, the evidence is mixed at best. FY2025 showed the plant can earn high-single-digit operating margins at about KRW 20bn of revenue. H1 2026 showed how quickly one customer and one market can remove half of revenue. The individually-recognised ingredient programme is the right strategic answer, but approvals are 2027 events at the earliest, and the company has a record of slipping timelines. The eLBP platform should be valued at close to zero until partnered.

Governance has improved formally, with an audit committee, independent directors and the 3% rule. However, both co-CEOs are insiders, one of whom runs the parent, and minority protection rests largely on Whan In's intentions.

Net assessment: a deep-value, low-quality special situation. The downside is cushioned by cash and the upside depends on capital allocation and execution; there is no earnings momentum. Close monitoring of the Q3 2026 disclosure on use of proceeds is warranted before any constructive stance.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameTitleAppointed / tenureBackground (as disclosed or reported)

Lee Won-beom (이원범)

Co-CEO and inside director

Director and CEO since 15 Oct 2024

CEO of Whan In Pharmaceutical (largest shareholder); second-generation owner, son of Whan In chairman Lee Kwang-sik; holds 3.27% of Whan In (Dealsite)

Park Myeong-su (박명수)

Co-CEO and inside director

Inside director since Mar 2022; CEO since 2 Mar 2023

Long-time BIFIDO executive. Chaired the June 2024 KMB bifidobacteria symposium; bought BIFIDO shares personally in June 2024

Cho Ju-yeon (조주연)

Outside (independent) director; audit committee

Since 15 Oct 2024

—

Lee Dong-su (이동수)

Outside (independent) director; audit committee

Since 15 Oct 2024

—

Cho Han-ju (조한주)

Outside (independent) director; audit committee

Since 15 Oct 2024

—

Baek Su-ok (백수옥)

Head of Management Division (reporting officer)

—

Signs DART filings as preparer

“—” = not publicly disclosed.

Board & Management Changes

DateChangeContext

14 Sep 2021

Founder Ji Geun-eog resigns as director; Shin Yong-cheol, Park Chan-ju, Lee Sang-hee (inside) and Kim Mi-ri (outside) join

Amicogen takeover

22 Mar 2022

Kwon Bin and Park Myeong-su join as inside directors; Park Seong-hwan as outside director

—

31 Aug 2022

Kwon Bin resigns as director

—

2 Mar 2023

Park Myeong-su becomes CEO (co-CEO with Shin Yong-cheol)

—

23 Mar 2023

Han Nok-yeop joins as outside director

—

21 Sep 2023

Kim Byung-hwan appointed statutory auditor (replacing Sung Jin-hyuk)

—

27 Mar 2024

Shin Ji-hye joins; Shin Yong-cheol, Lee Sang-hee and Kim Mi-ri re-appointed; Park Chan-ju leaves

—

15 Oct 2024

Lee Won-beom becomes co-CEO; Shin Yong-cheol, Lee Sang-hee, Shin Ji-hye, Kim Mi-ri, Han Nok-yeop and auditor Kim Byung-hwan leave; three new outside directors

Whan In takeover after the embezzlement; Amicogen-era management exits

Major Shareholders

HolderSharesStake (%)Date

Whan In Pharmaceutical Co., Ltd.

2,454,00030.00

30 Jun 2026

Ji Geun-eog (founder)

428,8425.24

30 Jun 2026 (424,436; 5.19% at FY2025 year-end)

Kwon Bin (former director / vice president)

296,5123.62

30 Jun 2026

Officers (aggregate)

90,1131.10

30 Jun 2026

Other shareholders

4,910,53360.04

30 Jun 2026

Competitive Landscape

Competitors by Segment

SegmentCompetitorTypeRelative positioning versus BIFIDO

Korean probiotic brands, ingredients and exports

Cell Biotech (쎌바이오텍, KOSDAQ 049960; "Duolac")

Listed probiotic specialist

About 2.7x BIFIDO's revenue; 11 strains with FDA GRAS (it claims the world's most); 55 export countries; consistently profitable; pays dividends

Korean probiotic ingredients

Medyogen (메디오젠)

Private strain/ingredient maker

—

Korean HFF ODM

Kolmar BNH (KOSDAQ)

Large HFF ODM

—

Korean HFF ODM

Cosmax NBT

HFF ODM

—

Korean HFF ODM

Novarex (KOSDAQ)

HFF ODM with individually-recognised ingredient portfolio

—

Korean consumer probiotics

hy (formerly Korea Yakult)

Dairy and probiotic brand

—

Korean consumer probiotics

Chong Kun Dang Health ("Lacto-fit")

Consumer HFF brand

—

Korean consumer HFF

GC Wellbeing (녹십자웰빙)

Named by THE VC as a peer

—

Global probiotic ingredients

Novonesis (Chr. Hansen), IFF (Danisco), Morinaga Milk (BB536), Probi AB, Lallemand, Kaneka Probiotics

Multinational strain suppliers

Orders of magnitude larger; set global price and quality benchmarks; compete for GRAS-grade infant and supplement strains

Microbiome therapeutics (Korea)

KoBioLabs, Genome & Company, CJ Bioscience, BioMe (Celltrion-backed)

LBP developers

BIFIDO has exited the clinical LBP race; BiGeX is pre-clinical

Peer Comparison FY2025

MetricBIFIDOCell BiotechKolmar BNHNovarex

Revenue FY2025 (KRW Bn)

19.753.1

n/v

n/v

Revenue growth FY2025 (%)

59.36.4

n/v

n/v

Operating income FY2025 (KRW Bn)

1.47.9

n/v

n/v

Operating margin FY2025 (%)

7.114.9

n/v

n/v

Net income FY2025 (KRW Bn)

-0.210.1

n/v

n/v

R&D intensity (%)

8.2 (S&P basis) / 11.5 (company gross)

n/v

n/v

n/v

P/E (x)

11.8 (TTM Jun-26)

8.52

n/v

n/v

P/B (x)

0.451.05

n/v

n/v

Dividend yield (%)

03.94

n/v

n/v

Market cap (KRW Bn)

21.8143.2

n/v

n/v

Peer Comparison FY2025 (Annual)

MetricFY2021FY2022FY2023FY2024FY2025

BIFIDO revenue (KRW Bn)

12.114.618.612.419.7

Cell Biotech revenue (KRW Bn)

46.950.553.849.953.1

BIFIDO operating income (KRW Bn)

-1.01.3-0.3-4.51.4

Cell Biotech operating income (KRW Bn)

7.36.12.26.87.9

Company Snapshot

$13.8M

Revenue

83

Employees

1999

Founded

Gangwon State, South Korea

Headquarters

SWOT Analysis

Strengths

  • US regulatory moat for core strains. BGN4, BORI and AD011 hold FDA GRAS (GRN 814, 813, 952) and NDI (1079, 1082, 1118). BGN4 is USP-listed (FY2025 business report; FDA records).
  • Broad, current IP estate. 58 registered patents at Jun 2026, 13 granted in 2025 alone, plus 29 pending applications and 146 registered trademarks.
  • Integrated GMP manufacturing. Production output of KRW 10.7bn in FY2025; GMP since 2006; China FSMP factory certification.
  • Ingredient-pricing power abroad. Average export raw-powder price rose from KRW 363,858/kg (FY2023) to KRW 477,656/kg (H1 2026).
  • Rebuilt liquidity. KRW 25.4bn property sale closed 14 Aug 2026, against a market cap of about KRW 21.8bn.
  • Strategic owner. Whan In (consolidated FY2024 revenue KRW 259.6bn per company profiles) holds 30% and installed its CEO as BIFIDO co-CEO.

Weaknesses

  • Customer concentration. Customer A was 31.93% of FY2025 revenue. Its sales fell from KRW 3,078m (H1 2025) to KRW 762m (H1 2026).
  • No domestic own-brand franchise. Domestic own-brand sales were zero in FY2025 and H1 2026; own-brand share fell from 28.5% to 4.3%.
  • Persistent sub-par returns. Five-year average ROE is about 0.5%; FY2024 net loss KRW −5.4bn; FY2025 consolidated net loss KRW −0.2bn.
  • Internal-control failure. KRW 8.08bn embezzlement by the head of finance in June 2024 (15.6% of equity).
  • Capital-allocation track record. KRW 32bn of real-estate capex later sold; KRW 3.0bn equity investment written to zero; repeated associate losses (Ropi Bio: KRW 1.56bn, 1.76bn and 1.24bn in FY2023–FY2025).
  • Thin R&D bench. 17 R&D staff; therapeutic programmes suspended.

Opportunities

  • Individually-recognised ingredients. Hypersensitive-skin approval targeted H1 2027; body-fat filing targeted Aug 2026. These would enable exclusive, higher-margin ingredient and B2C sales.
  • China infant-strain registration (2028 registration, 2029 commercialisation target) could unlock infant-formula ingredient supply.
  • Parent distribution synergies through Whan In and AsU.
  • Animal health. Livestock-pathogen patents (Dec 2025 – Jan 2026) and about 33 pet products already launched.
  • BiGeX out-licensing potential. A platform able to carry multiple payloads (immunotoxin, endolysin).
  • Capacity expansion at Hongcheon, funded by sale proceeds as stated in the FY2025 report.

Threats

  • China policy risk. Overseas revenue −60% in FY2024 and −61.7% in H1 2026 (year on year).
  • Price competition in notified probiotics; peers such as Cell Biotech have scale (KRW 53.1bn revenue) and dividends.
  • Regulatory risk for eLBPs. The company itself flags GMO safety, manufacturing and environmental-risk reviews.
  • Market-integrity flags. KRX "investment caution" designation on 18 May 2026 for trading concentrated in a few accounts.
  • Associate / FVTPL valuation risk. Ropi Bio recoverable value relies on an 8-year plan at an 11.8% discount rate and −1.5% terminal growth; the KRW 6.4bn bond is a Level-3 asset.
  • Talent and scale disadvantage against multinational strain suppliers (Novonesis, IFF, Morinaga).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
30 Apr 2025KOSDAQ section (소속부) reassignment disclosedAdministrative; follows the Oct 2024 move off the administrative-issue list
15 May 2025Q1 2025 quarterly reportStart of FY2025 recovery
17 Jun 2025Patent granted: vitamin ACE antioxidant coating for probioticsFormulation IP supporting ambient stability
Jun 2025Halitosis ingredient paper published; human-study track haltedNarrows the individually-recognised pipeline
1 Jul 2025Patent granted: RAPO + LRC5264 immune-balance complexIngredient IP
18 Jul 2025Gangnam Microbiome Center receives use approvalConstruction complete; triggers monetisation decision
1 Aug 2025Board approves acquisition of equity-linked bonds (KRW 7.0bn)Capital allocation into a non-core financial asset
14 Aug 2025H1 2025 report: revenue KRW 11.1bn, operating income KRW 1.4bnStrongest half in years; customer A KRW 3.1bn
18 Aug 2025Press: Whan In partly disposes of treasury shares, citing investment in HFF (BIFIDO) and animal healthParent signals funding capacity for BIFIDO-linked growth
20 Aug 2025Patent granted: *L. paracasei* OK strainOral-health IP
4 Sep 2025Microbiome Center classified as held for sale (KRW 24.8bn)Balance-sheet repositioning
29 Sep 2025Patent granted: BGN4 for COVID-19Strain-claim breadth
H2 2025RA Phase 1 IND voluntarily withdrawnExit from clinical-stage therapeutics
23 Oct 2025Patent granted: BORI for COVID-19Strain-claim breadth
14 Nov 2025Q3 2025 quarterly report—
5 Dec 2025Two patents granted: BGN4 and BORI for osteoarthritisStrain-claim breadth
15 Dec 2025Two patents granted: BGN4 and AD011 for livestock pathogen diseaseAnimal-health extension
16 Dec 2025Shareholder register record-date noticeRoutine AGM preparation
22 Dec 2025Appraisal-based impairment review of held-for-sale property: no impairmentSupports the later KRW 25.4bn price
3 Jan 2026Patent granted: RAPO strain detection method—
23 Jan 2026Patent granted: BORI for livestock pathogens; KRW 2.0bn Woori Bank loan (4.35%) matures and is repaid in H1Animal health; deleveraging
24 Feb 2026Disclosure of ≥30% change in revenue/profit structure (FY2025 vs FY2024); AGM convenedFY2025 revenue +59%, swing to operating profit
3 Mar 2026Patent granted: HHuMin-U anti-norovirus—
11 Mar 2026FY2025 business report and audit report filedConsolidated revenue KRW 19.7bn; net loss KRW −0.2bn
19 Mar 202627th AGM: articles amended (independent directors, 3% rule, committee rationalisation)Governance alignment with the Commercial Act revision
9 Apr 2026Board approves KRW 25.4bn sale of Daechi-dong land and building; KRW 2.54bn deposit receivedMajor liquidity event (41% of assets)
6 May 2026Patent granted: RAPO for systemic sclerosis and pulmonary fibrosisResidual therapeutic IP
15 May 2026Q1 2026 report (later corrected 24 Jul 2026)Revenue decline begins
18 May 2026KRX designates the stock as an "investment caution" issue for trading concentrated in a few accountsSpeculative-trading flag; low liquidity
19 May 2026Corrected disposal report: buyer re-papered to Kim YJ Co., Ltd.Transaction-execution risk addressed
14 Aug 2026Asset sale closes (KRW 22.86bn balance); H1 2026 report: revenue −45%, operating loss KRW −1.0bn, net income KRW +3.0bn (Ropi Bio gain)Cash rebuilt; core business weakening
Aug 2026 (target)Body-fat individually-recognised ingredient dossier submissionSubmission not publicly confirmed as of the cut-off

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

7 charts
Income Statement: Revenue & Gross Profit: Revenue rose from KRW 12,117 Mn in FY2021 to KRW 19,679 Mn in FY2025.
BIFIDO Co., Ltd — Income Statement: Revenue & Gross Profit
Series (KRW Mn)FY2021FY2022FY2023FY2024FY2025
Revenue12,11714,57918,63412,35019,679
Cost of sales7,9828,71711,2119,06512,189
Gross profit4,1355,8627,4233,2857,490

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. BIFIDO FY2025 business report (사업보고서, filed 11 Mar 2026) (financialfilings.com)
  2. BIFIDO H1 2026 semi-annual report (반기보고서, filed 14 Aug 2026) (financialfilings.com)
  3. Asset-transfer completion report (14 Aug 2026) (financialfilings.com)
  4. Corrected major-event report, tangible-asset disposal (19 May 2026) (financialfilings.com)
  5. Filing indexes 2025 and 2026 · financialfilings.com · company page (ISIN)
  6. S&P Global data via StockAnalysis (income statement, balance sheet, cash flow, statistics, profile) (stockanalysis.com)
  7. Butler (DART-based annual summary) (butler.works)
  8. Value Line Korea (valueline.co.kr)
  9. Kukinews, embezzlement and halt (27 Jun 2024) (kukinews.com)
  10. Kukinews, listing maintained (4 Oct 2024) (kukinews.com)
  11. Smart Today, embezzlement / Amicogen impact (smarttoday.co.kr)
  12. Smart Today, Amicogen sale to Whan In (smarttoday.co.kr)
  13. Daily Pharm, Whan In acquisition · dailypharm.com
  14. Dealsite, Amicogen stake sale (dealsite.co.kr)
  15. Dealsite, Lee Won-beom as CEO (dealsite.co.kr)
  16. Dealsite, Whan In treasury-share disposal (dealsite.co.kr)
  17. Dealsite, BFD1R KDDF selection (dealsite.co.kr)
  18. BIFIDO press release, listing maintained (2 Oct 2024) (file.alphasquare.co.kr)
  19. BIFIDO CEO letters and press releases (2024) · file.alphasquare.co.kr
  20. SK Securities initiation (May 2021) (file.alphasquare.co.kr)
  21. Biospectator, KOSDAQ listing (Dec 2018) (biospectator.com)
  22. eToday, IPO and GRAS outlook (Dec 2018) (etoday.co.kr)
  23. eToday, Hongcheon land and expansion (May 2020) (etoday.co.kr)
  24. Aju News, share price and US patent (Jun 2021) (ajunews.com)
  25. Medical Times, RA patent (Jul 2018) (medicaltimes.com)
  26. Medigate News, Amicogen–Ropi Bio investment (Nov 2021) (medigatenews.com)
  27. US FDA GRAS notice and response letters (GRN 813, 814, 875, 952) · fda.gov · fda.gov · fda.gov · fda.gov
  28. CPHI Online, strain profiles (GRN and NDI numbers, KCCM deposits) (cphi-online.com)
  29. THE VC, company profile and NPS headcount (thevc.kr)
  30. Investing.com, price data (ng.investing.com)
  31. StockHub, price data (stockhub.kr)
  32. Simply Wall St, overview (simplywall.st)
  33. Cell Biotech peer data · butler.works
  34. IMARC, Korea probiotics market (imarcgroup.com)
  35. IMARC global probiotics (via GII) (giikorea.co.kr)
  36. Mordor Intelligence, probiotics market (mordorintelligence.kr)
  37. Taiwan exhibitor listing (CHAMBIO) (chanchao.com.tw)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.